APA (7th ed.) Citation

DB, B., M, H., S, S., MA, F., A, M., O, C., . . . MJ, K. (2026). PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome. Journal of clinical medicine, 15(4), . https://doi.org/10.3390/jcm15041426

Chicago Style (17th ed.) Citation

DB, Beck, et al. "PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome." Journal of Clinical Medicine 15, no. 4 (2026). https://doi.org/10.3390/jcm15041426.

MLA (9th ed.) Citation

DB, Beck, et al. "PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome." Journal of Clinical Medicine, vol. 15, no. 4, 2026, https://doi.org/10.3390/jcm15041426.